Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

2010746 citationsJournal Article

Authors

Wendy De Roock · KU Leuven

Derek J. Jonker · Ottawa Hospital Research Institute

Federica Di Nicolantonio · University of Turin

Andrea Sartore‐Bianchi · Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Dongsheng Tu · Ontario Institute for Cancer Research

Salvatore Siena · Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Simona Lamba

Abstract

In this analysis, use of cetuximab was associated with longer overall and progression-free survival among patients with chemotherapy-refractory colorectal cancer with p.G13D-mutated tumors than with other KRAS-mutated tumors. Evaluation of cetuximab therapy in these tumors in prospective randomized trials may be warranted.

Topics & Keywords

Colorectal Cancer Treatments and Studies Genetic factors in colorectal cancer Gastric Cancer Management and Outcomes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA

Volume 304, Issue 16, pp. 1812-1812

DOI: 10.1001/jama.2010.1535

Field-Weighted Citation Impact: 43.15